Affiliation:
1. Digestive Diseases Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran Iran
2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran Iran
3. Digestive Oncology Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran Iran
Abstract
AbstractThe hepatitis C virus (HCV) continues to pose a significant public health challenge in Iran, mirroring a worldwide concern. This situation calls for a cohesive strategy that aligns with the World Health Organization's (WHO) goals for HCV elimination by 2030. Central to this strategy is targeting high‐risk groups, notably people who inject drugs and prisoners, with prevention, screening and treatment. The deployment of point‐of‐care testing and treatments in prisons and harm reduction facilities is vital. The adoption of cost‐effective generic direct‐acting antivirals represents a major step forward. Furthermore, innovative educational initiatives for healthcare providers and awareness campaigns for the public are critical. Additionally, tackling stigma, ensuring treatment affordability and upholding strict surveillance and data management, coupled with ongoing policy reviews, are vital components. This comprehensive and integrated approach is designed to drive Iran towards eliminating HCV and can serve as a blueprint for other countries with similar challenges.